$-0.10
(Market cap
$916 Mln
Revenue (TTM)
$57 Mln
P/E Ratio
--
P/B Ratio
4.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-131 Mln
-
ROE
-0.9 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2.1
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-6.7
-
Face value
--
-
Shares outstanding
20,744,900
10 Years Aggregate
CFO
$-400.60 Mln
EBITDA
$-327.36 Mln
Net Profit
$-361.61 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Albireo Pharma (ALBO)
| 104.3 | -1.2 | 92.5 | 60.1 | 23.6 | 5.4 | -6.3 |
|
BSE Sensex*
| -11.9 | -3.9 | -11.5 | -6.2 | 6.4 | 8.7 | 11.3 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|---|---|
|
Albireo Pharma (ALBO)
| -7.2 | -37.9 | 47.6 | 3.6 | -4.2 | 44.4 | 72.5 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Albireo Pharma (ALBO)
|
44.2 | 915.9 | 57.4 | -131.2 | -215.2 | -105.7 | -- | 4.3 |
| 4.0 | 387.3 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.1 | |
| 20.4 | 1,167.7 | 0.0 | -167.9 | -- | -128.7 | -- | 5.6 | |
| 12.9 | 2,257.7 | 550.0 | 458.1 | -3.3 | 45.9 | 5 | 1.8 | |
| 5.8 | 1,115.1 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 14.5 | 1,905.6 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.3 | |
| 12.6 | 916.7 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 68.3 | 3.4 | |
| 3.2 | 579.8 | 3.2 | -198.4 | -4,800.7 | -166.3 | -- | 7.6 | |
| 17.5 | 417.2 | 4.7 | -109.7 | -- | -30.2 | -- | 1.3 | |
| 19.6 | 2,089.8 | 453.3 | -178.1 | -27.8 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Albireo Pharma (ALBO)
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders.... The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts. As of March 1, 2023, Albireo Pharma, Inc. operates as a subsidiary of Ipsen Biopharmaceuticals, Inc.. Read more
-
CEO, Pres & Director
Mr. Ronald H. W. Cooper
-
CEO, Pres & Director
Mr. Ronald H. W. Cooper
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Albireo Pharma (ALBO)
What is the current share price of Albireo Pharma Inc (ALBO) Today?
The share price of Albireo Pharma Inc (ALBO) is $44.15 (NASDAQ) as of 02-Mar-2023 16:00 EDT. Albireo Pharma Inc (ALBO) has given a return of 23.6% in the last 3 years.
What is the current PB & PE ratio of Albireo Pharma Inc (ALBO)?
Since, TTM earnings of Albireo Pharma Inc (ALBO) is negative, P/E ratio is not available.
The P/B ratio of Albireo Pharma Inc (ALBO) is 4.30 times as on 02-Mar-2023, a 13 discount to its peers’ median range of 4.92 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-13.00
|
2.52
|
|
2020
|
-5.58
|
3.31
|
|
2019
|
-4.86
|
3.27
|
|
2018
|
-6.38
|
2.40
|
|
2017
|
-8.39
|
3.14
|
What is the 52 Week High and Low of Albireo Pharma Inc (ALBO)?
The 52-week high and low of Albireo Pharma Inc (ALBO) are Rs -- and Rs -- as of 12-May-2026.
What is the market cap of Albireo Pharma Inc (ALBO)?
Albireo Pharma Inc (ALBO) has a market capitalisation of $ 916 Mln as on 02-Mar-2023. As per SEBI classification, it is a company.
Should I invest in Albireo Pharma Inc (ALBO)?
Before investing in Albireo Pharma Inc (ALBO), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.